Who Paid My Doc
A Phase III, Observer-Blind, Randomized, Multi-Country Study to Assess
Research payments
$380,674
Through program year 2022, $380,674 in research payments was reported against A Phase III, Observer-Blind, Randomized, Multi-Country Study to Assess, across 82 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $1,301 | 1 |
| 2020 | Research | $379,373 | 81 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- James Campbell Baltimore, MD Named on 12 payments
- Pamela Zegers Lincoln, NE Named on 11 payments
- Gary Schlichter Murray, UT Named on 8 payments
- Sahra Niazi Lincoln, NE Named on 7 payments
- Stephen Russell Lincoln, NE Named on 7 payments
- Mary Tipton South Jordan, UT Named on 6 payments
- Ryan Gottfredson Orem, UT Named on 6 payments
- Stephen Coleman Draper, UT Named on 5 payments
- Martin Levinson Bingham Farms, MI Named on 4 payments
- Ronke Dosunmu East Orange, NJ Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.